Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Ascorbic Acid + Melphalan in Relapsed Refractory Multiple Myeloma
NCT03602235Phase 1Completed
- Start
- Mar 2019
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ascorbic acid in multiple myeloma (MM). Primary endpoint: Number of treatment related adverse events. Started Mar 2019; status: completed.
02
Drugs
ascorbic acid
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03602235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602235.